Archive by Author

The Value of the RESI Innovator’s Pitch Challenge (IPC) 

15 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) prepares early-stage entrepreneurs for their Global Roadshow Campaign. There are many tools in the LSN toolkit that we provide to make this happen. One of the tools is the Innovator’s Pitch Challenge (IPC). A key component of the Redefining Early Stage Investments (RESI) Conference Series, the Innovator’s Pitch Challenge (IPC), is an opportunity for early-stage life science and healthcare companies to apply to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts. Each finalist company also prepares a posterboard to be showcased in the exhibit hall and competes for “RESI Cash,” which attendees use to “invest” in their favorite presenters for the final prizes. The value of the Innovator’s Pitch Challenge comes from the real-time critique IPC finalists receive from the judging panel and the experience the finalists gain by pitching their technology to relevant industry leaders.

We are accepting applications for the RESI South 2024 Innovator’s Pitch Challenge until Wednesday, February 21. Learn more about the IPC and apply here!

Hear from past IPC finalists and Investor Judge: 

Vanessa WilliamsonVanessa Williamson, CEO, Gliachem:“A 4-minute pitch is not easy. There is an opportunity to add a bunch more content than you would with just a standard elevator pitch, but you can’t overload. Coming up with a succinct message that focused on the problem, solution, differentiation and market opportunity was key. As tempting as it was to get deep into the science, we focused on the business opportunity. The LSN and RESI resources were also invaluable. We attended the prep session you offered and followed the recommendations with respect to focus.”


Alberto Ramos VernieriDr. Alberto Ramos Vernieri, Chief Scientific Officer, Untech:“This prize is exactly that because the judges of the contest are people with a lot of experience and well recognized in the field. Each question from this kind of person is always useful to learn more about those things you can’t learn in other ways.”


Dr. Gennady Bratslavsky, Co-Founder & Partner at Avicella Capital:“An opportunity for us to have a good deep look during the presentations. It also gives an opportunity to provide feedback…It is an opportunity to put their best foot forward and an opportunity to have great exposure.”


David MedinaDavid Medina, PhD, Co-founder at Novaurum Biosciences:“I had the opportunity to pitch for the first time at RESI in Boston.  I was impressed by the quality of the questions I was asked by the investor judges, and it was great to be able to continue the conversation over a drink at the end of the day. We are currently still in conversation with some of them. I also think it helped us get more meetings with investors at RESI. A great experience!” 

To learn more and hear about how to prepare for the IPC, LSN offers free webinars. You can listen here to a previous recording Preparing for the Innovator’s Pitch Challenge.

Applications for the Innovator’s Pitch Challenge are now open for RESI South.

RESI-South-2024_02062024.

Register-now-button-new

Introducing Panelists on the Seed Funds Panel at RESI South 

15 Feb

Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

Life Science Nation (LSN) has curated a program of investor panels for our first RESI South, set to take place in person on March 25th in Atlanta, GA and virtually on March 26-27. We are thrilled to announce a compelling lineup for the Seed Funds panel, featuring 5 dynamic investors who specialize in providing seed-stage financing to startups in the life science and healthcare sectors.

The discussion will center on strategies and approaches on investing in the earliest stage of life science/healthcare assets. The panelists will delve into considerations investors face when dealing with high-risk, high-reward opportunities, what they look for when assessing these prospects, tactical advice for entrepreneurs seeking seed-stage financing, and much more. Our panelists represent a diverse range of backgrounds, expertise and geographic focuses, each bringing a unique perspective and wealth of experience to the table, making this discussion invaluable for fundraising entrepreneurs or investors looking to expand their portfolio. Please see below for the panelist lineup:


Peter Alff
Senior Venture Partner
Orange Grove Bio

Sinclair Dunlop
Managing Partner
Epidarex Capital

Deborah Hemingway
Managing Partner
Ecphora Capital

Michelle (Waye) Leeuwon
Program Manager for Product Development
Cancer Prevention and Research Institute of Texas (CPRIT)

Ron Levin
Managing Partner
Alumni Ventures

At LSN, we recognize the pivotal role that early-stage investments play in driving innovation and shaping the future of healthcare, and through our RESI panels, we aim to cultivate dialogue between investors and entrepreneurs, offering actionable insights and unparalleled networking opportunities.

We look forward to fostering connections and communications between the local ecosystem and the broader life science and healthcare innovation community through our inaugural RESI South. Join us in-person on March 25th or virtually on March 26-27, and we can’t wait to see you there!

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

Hot Investor Mandate: Family Office Backed Investment Fund Seeks Life Science & Healthcare Companies in Australia and Beyond

15 Feb

An investment firm based in Australia is backed by one of Australia’s largest family offices. With its current fund, the firm will focus exclusively on life sciences & healthcare. The firm is focused on investing early-stage companies – while the firm has a focus on supporting the Australian ecosystem, the firm is open to global opportunities. 
 
The firm seeks to invest in therapeutics, diagnostics, and digital health companies and has no particular preference on specific types of technologies or disease area/indication. The firm prefers to see strong pre-clinical data, and is open to both pre-clinical and clinical projects. The firm does not invest in medical device companies at this time. 
 
The firm seeks to support companies with innovative technology, and is open to working with both first-time and experienced management teams. The firm can act as either lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: US & Europe-Based Investment Group Allocates Up to $60M in Therapeutics, Devices, and Diagnostics Companies From Early Clinical Stage

15 Feb

An investment group located in the U.S. and Europe invests in early-stage life science companies from Seed to Series C. Typical check size can be up to $60M USD and varies depending on the fit. The firm makes investments to global companies acting as both a lead and co-investor. 
 
The firm is seeking to invest in biotech therapeutics, diagnostics, and medical devices. The firm is indication- and sub sector-agnostic and can fund companies from Phase I to Phase IV. 
 
The firm does not require to take a board seat, but rather seeks to run the clinical trial programs in exchange. The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Family Office Invests in Technologies Addressing CNS Diseases and Disorders, Seeking Global Opportunities

15 Feb

A family office based in the US makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania. 
 
The firm funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Angel Group Seeks Early-Stage Investments in Medtech and Digital Health in Cardiology, Neurology, and More

15 Feb

An angel syndicate headquartered in Baltimore, Maryland. The group invests in device, diagnostics, and digital health companies globally. The group will invest as early as Seed rounds up to Series B. Typical check size falls between $250k-1M USD and prefers to co-invest. The firm will invest through equity or convertible notes. 
 
The firm invests in medical devices, digital health, and diagnostics. The firm does not invest in therapeutics. In terms of devices, the firm is open to all classes of devices. Current interest is in cardiology, structural heart, and neurology, but the firm is indication-agnostic. Although there is preference with earlier stages of development, the firm is stage-agnostic. 
 
The firm may take a board seat on a case-by-case basis. The firm requires companies to have at least one full time executive.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

LSN: Navigating the Path to Commercialization

8 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

By helping startups develop compelling narratives for their fundraising campaigns and facilitating strategic partnerships through its extensive network, LSN plays a pivotal role in bridging the gap between academia and industry. Life Science Nation has developed a set of products and services that help startups navigate the fundraising chasm and find the right partners to aid them in their journey to commercialization. These challenges include:

  1. Navigating a New Field: Moving from academia to industry requires adapting to a new environment, understanding the rules, and building a professional network within the life science industry.
  2. Acquiring New Skillsets: Scientists-Entrepreneurs need to be open to learning or having staff that understand Sales, Marketing, and Business Development.
  3. Fundraising, Licensing, and Collaboration Trends: Early-stage life science companies face the challenge of staying informed about investment trends and securing funding, especially in the face of broader market challenges and uncertainties.
  4. Competition and Innovation: Rapid innovation and competition characterize the life science industry. To remain competitive, startups must stay abreast of the latest scientific advancements and disruptive technologies.
  5. Networking and Collaboration: Building a strong network of collaborators, investors, and partners is essential for early-stage life science companies. This includes understanding the dynamics of potential partnerships and effectively engaging with investors and partners.
  6. Market Dynamics and Global Expansion: Understanding market dynamics, both locally and globally, is crucial for startups. They must also develop a strategic plan for global expansion and navigate the complexities of launching and executing a global campaign and roadshow.
  7. Fostering Ongoing Partnerships: Successful partnerships require ongoing effort and a dedicated plan to maintain a consistent pipeline of partner meetings, even as these meetings ebb and flow over time.

Contrary to the popular assumption that science is enough, and focusing on that will lead to successful fundraising, making the transition from a scientist to an entrepreneur requires flexibility, passion, and a lot of drive and determination. A scientist has to transform and adapt, learning new skill sets and entering a new world, but those that want it can be extremely successful. Let us help you on that journey.

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100